Lunit Inc. (KOSDAQ:328130)

South Korea flag South Korea · Delayed Price · Currency is KRW
12,030
+2,150 (21.76%)
Jun 29, 2026, 3:30 PM KST
Market Cap894.82B -34.7%
Revenue (ttm)87.88B +28.8%
Net Income-67.09B
EPS-1,518.67
Shares Out 74.38M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume613,556
Open10,050
Previous Close9,880
Day's Range10,050 - 12,200
52-Week Range9,650 - 30,350
Beta1.12
Analystsn/a
Price Targetn/a
Earnings DateAug 11, 2026

About Lunit

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such a... [Read more]

Sector Technology
Founded 2013
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 328130
Full Company Profile

Financial Performance

In 2025, Lunit's revenue was 83.13 billion, an increase of 53.43% compared to the previous year's 54.18 billion. Losses were -47.39 billion, -42.69% less than in 2024.

Financial Statements